English 日本語

#rusfertide

List of IR information related to "rusfertide".

2 IR Posts
1 Companies
1 days ago Last Updated

Filters

Reset
Period:
Importance:
2 IR Posts
4502 Takeda Pharmaceutical Company Limited
2026/03/02
Acceptance of New Drug Application by the U.S. Food and Drug Administration for rusfertide, a Potential First-in-Class Treatment for Polycythemia Vera, in Collaboration with Protagonist Therapeutics, and Its Designation for Priority Review

Takeda Pharmaceutical announces that the U.S. FDA has accepted the new drug application for rusfertide, co-developed with Protagonist Therapeutics, and granted it priority review designation. The target date for review completion is Q3 2026.

#TakedaPharmaceutical #NewDrugApplication #rusfertide
4502 Takeda Pharmaceutical Company Limited
2025/12/08
Announcement of Long-term rusfertide Data Demonstrating Sustained Hematocrit Control in Polycythemia Vera at the 67th Annual Meeting of the American Society of Hematology (ASH) in Collaboration with Protagonist Therapeutics

Takeda Pharmaceutical Company Limited, in collaboration with Protagonist Therapeutics, announced 52-week data from the Phase 3 VERIFY trial of rusfertide in patients with polycythemia vera, demonstrating sustained hematocrit control and safety.

Strategy/Investment,Other
#TakedaPharmaceuticalCompanyLimited #rusfertide #NewProduct
Scroll to Top